Trial Profile
A Single Dose Clinical Trial to Study the Safety of ART-I02 in Patients With Arthritis
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2022
Price :
$35
*
At a glance
- Drugs ART I02 (Primary)
- Indications Osteoarthritis; Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors MeiraGTx Netherlands
- 13 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 08 Jul 2018 According to an Arthrogen media release, based on anticipated enrollment and follow-up timelines, the first set of data is expected to be available in the fourth quarter of 2018.
- 08 Jul 2018 According to an Arthrogen media release, the first three arthritis patients for the first cohort from this trial have been enrolled.